Last reviewed · How we verify

Ticlopidine and itraconazole — Competitive Intelligence Brief

Ticlopidine and itraconazole (Ticlopidine and itraconazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent + Antifungal agent. Area: Cardiovascular / Infectious Disease.

marketed Antiplatelet agent + Antifungal agent ADP receptor (P2Y12) for ticlopidine; Fungal CYP51 for itraconazole Cardiovascular / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ticlopidine and itraconazole (Ticlopidine and itraconazole) — Turku University Hospital. This is a combination of ticlopidine (a platelet aggregation inhibitor) and itraconazole (an antifungal agent), used together to manage thrombotic and fungal complications.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ticlopidine and itraconazole TARGET Ticlopidine and itraconazole Turku University Hospital marketed Antiplatelet agent + Antifungal agent ADP receptor (P2Y12) for ticlopidine; Fungal CYP51 for itraconazole

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent + Antifungal agent class)

  1. Turku University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticlopidine and itraconazole — Competitive Intelligence Brief. https://druglandscape.com/ci/ticlopidine-and-itraconazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: